{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:51Z","timestamp":1792001451476,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>SSc is an autoimmune disease characterized by excessive fibrosis in multiple organs, including the gastrointestinal (GI) tract. GI symptoms of SSc such as intestinal pseudo-obstruction (IPO) are often refractory to conventional intervention and can result in longer in-hospital stay or even increased mortality. We aimed to summarize the insights to date regarding the efficacy of IVIG against GI symptoms of SSc to unveil what we should focus on in future studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Herein we report the response of GI symptoms in three cases with SSc-myositis overlap who received IVIG administration. We also conducted a systematic literature review to summarize previous reports regarding the efficacy of IVIG upon the GI manifestations of SSc, according to the PRISMA 2020 guideline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The case series demonstrated remarkable and rapid improvement of GI symptoms, including IPO, after IVIG administration. The literature review revealed that previous reports also support the efficacy and safety of IVIG against GI manifestations of SSc. However, they were all retrospective studies and lacking description of the short-term outcome after IVIG administration with objective and quantitative metrics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IVIG seems to be a promising therapeutic option for the management of GI symptoms in SSc, including IPO. Investigators should focus more on short-term outcomes to properly assess the therapeutic benefit of IVIG, ideally using reliable quantitative measures in a multicentre randomized placebo-controlled setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead093","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:34:44Z","timestamp":1677245684000},"page":"3139-3145","source":"Crossref","is-referenced-by-count":19,"title":["Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8047","authenticated-orcid":false,"given":"Kazuki M","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kuzumi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Awaji","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Tokyo Graduate School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"2023090115162165500_kead093-B1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2023090115162165500_kead093-B2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3899\/jrheum.110826","article-title":"Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis","volume":"39","author":"Omair","year":"2012","journal-title":"J Rheumatol"},{"key":"2023090115162165500_kead093-B3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/rheumatology\/kev393","article-title":"Concise report Intestinal pseudo-obstruction in patients with systemic sclerosis\u202f: an analysis of the Nationwide Inpatient Sample","volume":"55","author":"Valenzuela","year":"2016","journal-title":"Rhematology"},{"key":"2023090115162165500_kead093-B4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2023090115162165500_kead093-B5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2023090115162165500_kead093-B6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023090115162165500_kead093-B7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology"},{"key":"2023090115162165500_kead093-B8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"key":"2023090115162165500_kead093-B9","first-page":"S214","article-title":"Successful treatment of a refractory dysbiotic intestinal pseudo-obstruction in a patient with systemic sclerosispolymyositis overlap syndrome by intravenous immunoglobulin administration possibly related to gut flora normalisation","volume":"35","author":"Kamei","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2023090115162165500_kead093-B10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","article-title":"A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion","volume":"44","author":"Asano","year":"2005","journal-title":"Rheumatology"},{"key":"2023090115162165500_kead093-B11","first-page":"s151","article-title":"Intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2023090115162165500_kead093-B12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2008.096545","article-title":"Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility","volume":"68","author":"Kawaguchi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023090115162165500_kead093-B13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1152\/ajpgi.00286.2009","article-title":"Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells","volume":"297","author":"Singh","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2023090115162165500_kead093-B14","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2023090115162165500_kead093-B15","first-page":"2050","article-title":"Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement","volume":"34","author":"Nishimagi","year":"2007","journal-title":"J Rheumatol"},{"key":"2023090115162165500_kead093-B16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.23479","article-title":"Determining the risk factors and clinical features associated with severe gastrointestinal dysmotility in systemic sclerosis","volume":"70","author":"Mcmahan","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2023090115162165500_kead093-B17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2019.05.005","article-title":"Evaluation of risk factors for pseudo-obstruction in systemic sclerosis","volume":"49","author":"Dein","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023090115162165500_kead093-B18","author":"Buchanan","year":"2022"},{"key":"2023090115162165500_kead093-B19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Care Res"},{"key":"2023090115162165500_kead093-B20","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead093\/49806363\/kead093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3139\/51329118\/kead093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3139\/51329118\/kead093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:40:56Z","timestamp":1693582856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/9\/3139\/7056633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,2,24]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead093","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,2,24]]}}}